Special Article
Free Access
Is glucuronidation truly preserved in patients with liver disease?
Anastacio M. Hoyumpa M.D.,
Steven Schenker,
Corresponding Author
Anastacio M. Hoyumpa M.D.
Department of Medicine, Division of Gastroenterology and Nutrition, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284–7878
7703 Floyd Curl Drive, San Antonio, TX 78284-7878===Search for more papers by this authorSteven Schenker
Department of Medicine, Division of Gastroenterology and Nutrition, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284–7878
Search for more papers by this authorAnastacio M. Hoyumpa M.D.,
Steven Schenker,
Corresponding Author
Anastacio M. Hoyumpa M.D.
Department of Medicine, Division of Gastroenterology and Nutrition, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284–7878
7703 Floyd Curl Drive, San Antonio, TX 78284-7878===Search for more papers by this authorSteven Schenker
Department of Medicine, Division of Gastroenterology and Nutrition, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284–7878
Search for more papers by this author
References
- 1 Zaphiropoulos PG, Mode A, Norstedt G, Gustaffson JA. Regulation of sexual differentiation in drug and steroid metabolism. Trends Pharmacol Sci 1989; 10: 149–153.
- 2 Gregus Z, Watkins JB, Thompson TN, Klaassen CD. Resistance of some phase II biotransformation pathways to hepatotoxins. J Pharmacol Exp Ther 1982; 222: 471–479.
- 3 Testa B, Jenner P. Drug metabolizing enzyme system. In: Drug metabolism: chemical and biochemical aspects. Chap. 21. New York: Marcel Dekker, Inc, 1976; 273–328.
- 4 Baron J, Redick JA, Guengerich FP. Immunohistochemical localizations of cytochrome P-450 in rat liver. Life Sci 1978; 23: 2627–2632.
- 5 Gumucio JJ, DeMason LJ, Miller DL, Krezoski SD, Keener M. Induction of cytochrome P-450 in a selective subpopulation of hepatocytes. Am J Physiol 1978; 234: C102–C109.
- 6 Pang S, Terrell JA. Retrograde perfusion to probe the heterogenous distribution of hepatic drug metabolizing enzymes in rats. J Pharmacol Exp Ther 1981; 216: 339–346.
- 7 Koster H, Halsema I, Scholtens E, Pang KS, Mulder GJ. Kinetics of sulfation and glucuronidation in the perfused rat liver preparation. Biochem Pharmacol 1982; 31: 3023–3028.
- 8 Dawson JR, Weitering JG, Stilwell RN, Pang KS. Alterations of transit time and directions of flow to probe the heterogenous distribution of conjugating activities for hormol in the perfused rat liver. J Pharmacol Exp Ther 1985; 234: 691–697.
- 9 Desmond PV, James R, Schenker S, Gerkens JF, Branch RA. Preservation of glucuronidation in carbon tetrachloride-induced acute liver injury in the rat. Biochem Pharmacol 1981; 30: 993–999.
- 10 James R, Desmond PV, Kupfer A, Schenker S, Branch RA. The differential localization of various drug metabolizing systems within the rat liver lobule as determined by the hepatotoxins allyl alcohol, carbon tetrachloride, and bromobenzene. J Pharmacol Exp Ther 1981; 217: 127–132.
- 11 Mitchell MC, Hamilton R, Wacker L, Branch RA. Zonal distribution of paracetamol glucuronidation in the isolated perfused rat liver. Xenobiotica 1989; 19: 389–400.
- 12 Mouelhi M, Kauffman FC. Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver. HEPATOLOGY 1986; 6: 450–456.
- 13 Siest G, Fournel-Gigleux S, Magdalou J, Bagrel D. Cellular and molecular aspects of UDP-glucuronosyltransferases. Drug Metab Rev 1989; 20(2–4): 721–731.
- 14 Crooks J, O'Malley KO, Stevenson IH. Pharmacokinetics in the elderly. Clin Pharmacokinet 1976; 1: 280–296.
- 15 Triggs EJ, Nation RL. Pharmacokinetics in the aged: a review. J Pharmacokinet Biopharmacol 1975; 3: 387–418.
- 16 Woodhouse KW, Mutch E, Williams FM, Rawlins MD, James OFW. The effect of age on pathways of drug metabolism in human liver. Age Ageing 1984; 13: 328–334.
- 17 Maloney AG, Schmucker DL, Vessey DS, Wang RK. The effect of aging on the hepatic microsomal mixed-function oxidase system of male and female monkeys. HEPATOLOGY 1986; 6: 282–287.
- 18 Wynne HA, Lope LH, Mutch E, Rawlins MD, Woodhouse KW, James OFW. The effect of age upon liver volume and apparent liver blood flow in healthy men. HEPATOLOGY 1989; 9: 297–301.
- 19 Wynne HA, James OFW. The ageing liver. Age Ageing 1990; 19: 1–3.
- 20 Angus PW, Morgan DJ, Smallwood RA. Review article: hypoxia and hepatic drug metabolism–clinical implications. Aliment Pharmacol Ther 1990; 4: 213–225.
- 21 Elliott SL, Angus PW, Ghabrial DS, Morgan DJ, Smallwood RA. Fasting increases the sensitivity of harmol glucuronidation to hypoxia [Abstract]. HEPATOLOGY 1990; 12: 400.
- 22 Klotz U, Reiman I. Delayed clearance of diazepam due to cimetidine. N Engl J Med 1980; 302: 1012–1014.
- 23 Desmond PV, Patwardhan RV, Schenker S, Speeg KV. Cimetidine impairs elimination of chlordiazepoxide (Librium®) in man. Ann Intern Med 1980; 93: 266–268.
- 24 Patwardhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker S, Speeg KV. Cimetidine spares the glucuronidation of lorazepam and oxazepam. Gastroenterology 1980; 79: 912–916.
- 25 Abernathy DR, Greenblatt DJ, Divoll M, Ameer B, Shader RI. Differential effects of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugations (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. J Pharmacol Exp Ther 1983; 224: 508–513.
- 26 Mitchell MC, Schenker S, Speeg KV. Selective inhibition of acetaminophen oxidation and toxicity by cimetidine and other histamine H2 receptor antagonists in vivo and in vitro in the rat and in man. J Clin Invest 1984; 73: 383–391.
- 27 MacLeod SM, Sellers EM, Giles HG, Billings BJ, Martin PR, Greenblatt DJ, Marshman JA. Interactions of disulfiram with benzodiazepines. Clin Pharmacol Ther 1978; 24: 583–589.
- 28 Abernethy DR, Divoll M, Ochs HR, et al. Increased metabolic clearance of acetaminophen with oral contraceptive use. Obstet Gynecol 1982; 60: 338–341.
- 29 Patwardhan RV, Mitchell MC, Johnson RF, Schenker S. Differential effects of oral contraceptive steroids on the metabolism of benzodiazepines. HEPATOLOGY 1983; 3: 248–253.
- 30 Ochs HR, Greenblatt DJ, Verburg-Ochs B, Matlis R. Differential effects of isonazid and oral contraceptive steroids on antipyrine oxidation and acetaminophen conjugation. Pharmacology 1984; 28: 188–195.
- 31 Watson KJR, Ghabreal H, Mashford ML, Harman PJ, Breen KJ, Desmond PV. The oral contraceptive pill increases morphine clearance, but does not increase hepatic blood flow [Abstract]. Gastroenterology 1986; 90: 1779.
- 32 Patwardhan RV, Desmond PV, Johnson RF, Schenker S. Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med 1980; 95: 603–608.
- 33 Roberts RK, Desmond PV, Wilkinson GR, Schenker S. Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives. Clin Pharmacol Ther 1979; 25: 826–831.
- 34 Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JR, Smith RB. Effect of oral contraceptives in triazolam, temazepam, alprazolam and lorazepam kinetics. Clin Pharmacol Ther 1984; 36: 683–690.
- 35 Gustavson LE, Legler UF, Benet LZ. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 1986; 62: 234–237.
- 36 Hoyumpa AM, Patwardhan R, Maples M, Desmond PV, Johnson RF, Sinclair AP, Schenker S. Effect of short-term ethanol administration on lorazepam clearance. HEPATOLOGY 1981; 1: 47–53.
- 37 Sellers EM, Giles HG, Greenblatt DJ, Naranjo CA. Differential effects on benzodiazepine disposition by disulfiram and ethanol. Arzneim Forsch 1980; 30: 882–886.
- 38 Mitchell MC, Hall SD, Schenker S, Branch RA. Impaired hepatic elimination of paranitrophenol and its metabolites in the rat following chronic ethanol pretreatment. Alcoholism: Clin Exp Res 1989; 13: 264–270.
- 39 Roberts R, Wilkinson GR, Branch RA, Schenker S. Effect of age and cirrhosis on the disposition and elimination of chlordiazepoxide. Gastroenterology 1978; 75: 479–485.
- 40 Klotz U, Avant GR, Hoyumpa AM, Schenker S, Wilkinson GR. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 1975; 55: 347–359.
- 41 Klotz U, McHorse TS, Wilkinson GR, Schenker S. The effect of cirrhosis in the disposition and elimination of meperidine on man. Clin Pharmacol Ther 1974; 16: 667–675.
- 42 McHorse TS, Wilkinson GR, Johnson RF, Schenker S. Effect of acute viral hepatitis on the disposition and elimination of meperidine. Gastroenterology 1975; 68: 775–780.
- 43 Hoyumpa AM, Schenker S. Major drug interactions: effect of liver disease, alcohol and malnutrition. Ann Rev Med 1983; 33: 113–149.
- 44 Secor J, Schenker S. Drug metabolism in patients with liver disease. Adv Intern Med 1987; 32: 379–406.
- 45 Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver disease. Pharmacol Ther 1989; 40: 439–479.
- 46 Shull HJ, Wilkinson GR, Johnson RF, Johnson R, Schenker S. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 1976; 84: 420–425.
- 47 Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR. The effects of aging and liver disease on the disposition of lorazepam in man. Clin Pharmacol Ther 1978; 24: 41–419.
- 48 Tschanz C, Wilson RL, Shand DG. The effects of cirrhosis on temazepam elimination. Clin Pharmacol Ther 1983; 33: 218.
- 49 Ghabrial H, Desmond PV, Watson KJR, Gijsbers AJ, Harman PJ, Breen KJ, Mashford ML. The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol 1986; 30: 93–97.
- 50 Ochs HR, Greenblatt DJ, Verburg-Ochs B, Matlis R. Temazepam clearance unaltered in cirrhosis. Am J Gastroenterol 1986; 81: 80–84.
- 51 Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther 1983; 33: 95–101.
- 52 Forrest JAH, Adrienssens P, Finlayson NDC, Prescott LF. Paracetamol metabolism in chronic liver disease. Eur J Clin Pharmacol 1979; 15: 427–431.
- 53 Bock KW, Wiltfang J, Blume R, Ullrich D, Bircher J. Paracetamol as a test drug to determine glucuronide formation in man: effect of inducers and smoking. Eur J Clin Pharmacol 1987; 31: 677–683.
- 54 Sellers EM, Greenblatt DJ, Giles HG, Naranjo CA, Kaplan H, McLeod SM. Chlordiazepoxide and oxazepam disposition in cirrhosis. Clin Pharmacol Ther 1979; 26: 240–246.
- 55 Patwardhan RV, Johnson RF, Hoyumpa AM, Sheehan JJ, Desmond PV, Wilkinson GR, Branch RA, et al. Normal metabolism of morphine in cirrhosis. Gastroenterology 1981; 81: 1006–1011.
- 56 Crotty B, Watson KJR, Desmond PV, Mashford ML, Wood LJ, Colman J, Dudley FJ. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol 1989; 36: 501–506.
- 57 Watson JKR, Desmond PV, Breen KJ, Mashford ML. Morphine disposition in cirrhosis [Abstract]. Gastroenterology 1985; 88: 1704.
- 58 Jacqz E, Ward S, Johnson RF, Schenker S, Gerkens J, Branch RA. Extrahepatic glucuronidation of morphine in the dog. Drug Metab Disp 1986; 14: 627–630.
- 59 Crotty B, Mashford ML, Desmond PV. There is no metabolism of morphine in the arm or lung in man [Abstract 144]. Clin Exp Pharmacol Physiol 1988; (Suppl #12).
- 60 Crotty B, Paull P, Mashford ML, et al. Sites of morphine metabolism in the dog [Abstract 19]. Clin Exp Pharmacol Physiol 1988; (Suppl #14).
- 61 Pacifici GM, Bencini C, Rane A. Presystemic glucuronidation of morphine in humans and rhesus monkeys: subcellular distribution of UDP-glucuronyltransferase in the liver and intestine. Xenobiotica 1986; 16: 123–128.
- 62 Yue O, Odar-Cederlof I, Sawe J. Glucuronidation of morphine in human kidney. Pharmacol Toxicol 1988; 63: 337–341.
- 63 Gerkens JF, Desmond PV, Schenker S, Branch RA. Hepatic and extrahepatic glucuronidation of lorazepam in the dog. HEPATOLOGY 1981; 1: 329–335.
- 64 Branch RA, Cotham R, Johnson RF, Porter J, Desmond PV, Schenker S. Periportal localization of lorazepam glucuronidation in the isolated perfused rat liver. J Lab Clin Med 1983; 102: 805–812.
- 65 Bock KW, Josting D, Lilienblum W, Pfeil H. Purification of rat liver microsomal UDP-glucuronyl-transferase: separation of two enzyme forms inducible by 3-methylcholantrene or phenobarbital. Eur J Biochem 1979; 98: 19–26.
- 66 Smyth FE, Desmond PV, Mashford ML. Comparison of oxidation and glucuronidation pathways in four models of liver injury [Abstract]. Gastroenterology 1989; 96: A662.
- 67 Watson KJR, Sotirellis N, Gollan JL, Desmond PV, Mashford ML, Sawyer WH. Enhanced microsomal UDP-glucuronyltransferase (GT) activity in rat cirrhosis is not due to altered membrane fluidity [Abstract]. Gastroenterology 1990; 98: A645.
- 68 Sonne J, Anderson PB, Loft S, Døssing M, Andreasen F. Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. HEPATOLOGY 1990; 11: 951–956.
- 69 Witassek F, Bircher J, Huguenin P, Preisig R. Abnormal glucuronidation of zomepirac in patients with cirrhosis of the liver. HEPATOLOGY 1983; 3: 415–422.
- 70 Smith PC, Langendijk PNJ, Bosso JA, Benet LZ. Effect of probenecid on the formation and elimination of acylglucuronide: studies with zomepirac. Clin Pharmacol Ther 1985; 38: 121–127.
- 71 Mazoit J-X, Sandouk P, Zetlaoui P, Shermann J-M. Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. Anesth Analg 1987; 66: 293–298.
- 72 Hasselstrom J, Erikson S, Persson A, Rane A, Svensson JO, Sawe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Chin Pharmacol 1990; 29: 289–297.
- 73 Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193–199.
- 74 Carrithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis. Ann Intern Med 1989; 110: 685–690.
- 75 Hoyumpa AM, Brown MW, Johnson RF, Troxell R, Snowdy PA, Schenker S. Effects of liver disease on the disposition of ciramadol in humans. J Clin Pharmacol 1989; 29: 217–224.
- 76 Hoyumpa AM, Snowdy P, Nichols S, Johnson R, Stump D. Effect of cirrhosis on the disposition of dezocine [Abstract]. Clin Pharmacol Ther 1987; 41: 226.
- 77 Taburet A-M, Naveau S, Zora G, Colin J-N, Delfraissy J-F, Chaput J-C, Singlas E. Pharmacokinetics of zidovudine in patients with liver disease. Clin Pharmacol Ther 1990; 47: 731–739.
- 78 Fletcher CV, Rhame F, Simpson M, Chinnock B, Chace B, De Miranda P, Balfour HH. Zidovudine pharmacokinetics in normals, AIDS/ARC, and AIDS patients with hepatic disease [Abstract]. Clin Pharmacol Ther 1989; 45: 182.
- 79 Martre-Sauvageon H, Bannie F, Tabah I, Rio B, Monsuez JJ, Oksenhandler E, Viemer E, et al. Pharmacokinetics of zidovudine in AIDS patients: influence of age and hepatic disorders [Abstract MBP 323]. 5th International Conference on AIDS. Ottawa: International Development Research Centre, 1989; 275.
- 80 Tartaglione T, Opheim K, Van der Horst C, Raasch R, Cheeseman S, High K. Pharmacokinetics of zidovudine in adult patients with HIV infection and hepatic disease. 5th International Conference on AIDS [Abstract MBP 332]. Ottawa: International Development Research Centre, 1989; 277.
- 81 Morse GD, Olson J, Portmore A, Taylor C, Plank C, Reichman RC. Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency (HIV) infection. Antiviral Res 1989; 11: 57–66.
- 82 Hoyumpa A, Ermer G, Cervallos W, Trevino H, Martin R, Bay M, Gonzalez R, et al. Comparison of phases I and II metabolism in liver disease. [Abstract]. HEPATOLOGY 1990; 12: 412.
- 83
Williams RL,
Upton RA.
The clinical pharmacology of ketoprofen.
J Clin Pharmacol
1988;
28: 513–522.
10.1002/j.1552-4604.1988.tb05971.x Google Scholar
- 84 Holazo AA, Chen SS, McMahon G, Ryan JR, Konikoff JJ, Brazzell RK. The influence of liver dysfunction in the pharmacokinetics of carprofen. J Clin Pharmacol 1985; 25: 109–114.
- 85 Bock KW, Clausbruck MC, Kaufmann R, Lilienblum W, Oesch F, Platt KL. Functional heterogeneity of UDP-glucuronyltransferase in rat tissues. Biochem Pharmacol 1980; 29: 495–500.
- 86 Bock KW, Josting D, Lilienblum W, Pfeil H. Purification of rat liver microsomal UDP-glucuronyltransferase: separation of two enzyme forms inducible by 3-methylcholanthrene or phenobarbital. Eur J Biochem 1979; 98: 19–26.
- 87 Dragaci S, Thomassin J, Magdalou J, Souhaili El Amri H, Boissel P, Siest G. Properties of human hepatic UDP-glucuronyltransferases: relationship to other inducible enzymes in patients with cholestasis. Eur J Pharmacol 1987; 32: 485–491.
- 88 Yue Q, Von Bahr C, Odar-Cederlof I, Sawe J. Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors. Pharmacol Toxicol 1990; 66: 221–226.
- 89 Tephly TR, Townsend M, Green MD. UDP-glucuronosyltransferases in the metabolic disposition of xenobiotics. Drug Metab Rev 1989; 20(2–4): 689–695.
- 90 Mackenzie PI. Rat liver UDP-glucuronosyltransferase: identification of cDNAs encoding two enzymes which glucuronidate testosterone dihydrotestosterone and B-estradiol. J Biol Chem 1987; 262: 9744–9749.
- 91 Mackenzie PI. Expression of chimeric cDNAs in cell culture defines a region of UDP-glucuronyltransferase involved in substrate selection. J Biol Chem 1990; 265: 3432–3435.
- 92 Coughtrie MWH, Ask B, Rane A, et al. The enantioselective gluronidation of morphine in rats and humans: evidence for the involvement of more than one UDP-gluronosyltransferase isoenzyme. Biochem Pharmacol 1989; 38: 3273–3280.
- 93 Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther 1980; 215: 86–91.
- 94 Lin JH, Chen I-W, Ulm EH, Duggan DE. Differential effects of phenobarbital on ester and ether glucuronidation of diflunisal in rats. J Pharmacol Exp Ther 1987; 242: 1013–1018.
- 95 Williams RL, Upton RA, Cello JP, Jones RM, Blitstein M, Kelly J, Nierenburg D. Naproxen disposition in patients with alcoholic cirrhosis. Eur J Clin Pharmacol 1984; 27: 291–296.
- 96 Juhl RP, Van Thiel DH, Dittert LW, Albert KS, Smith RB. Ibuprofen and sulindac kinetics in alcoholic liver disease. Clin Pharmacol Ther 1983; 34: 104–109.
- 97 Iwakawa S, Spahn H, Benet LZ, Lin ET. Steroselective binding of the glucuronide conjugates of carprofen inantiomers to human serum albumin. Biochem Pharmacol 1990; 39: 949–953.
- 98 Bigler D, Eriksen J, Broen-Christensen C. Prolonged respiratory depression caused by slow release of morphine. Lancet 1984; 1: 1477.
- 99 Shelly M, Park GR. Renal failure and use of morphine in intensive care. Lancet 1985; 1: 1100.
- 100 Mickie C, Chapman JR, Sear J, et al. Opioid metabolism and the kidney. Lancet 1985; 1: 586.
- 101 Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. BMJ 1986; 292: 1548–1549.
- 102 Wolff J, Bigler D, Broen-Christensen C, Rasmussen SN, Anderssen HB, Tonnesen KH. Influence of renal function on the elimination of morphine and morphine glucuronide. Eur J Clin Pharmacol 1988; 34: 353–357.
- 103 Shimomura K, Kamata O, Ueki S, Ida S, Oguri K, Yoshimura H, Tsukamoto. Analgesic effect of morphine glucuronides. Tohokushima J Exp Med 1971; 105: 45–52.
- 104 Villaneuva J-P, Fortunet-Fouin H, Arsone D. Cimetidine kinetics in patients with severe liver disease. HEPATOLOGY 1983; 3: 923–927.
- 105 Eknoyan G. Glomerular abnormalities in liver disease. In: M Epstein, ed. The kidney in liver disease. 2nd ed. New York: Elsevier Biomedical, 1983; 119–145.
- 106 Wood LJ, Massie D, McLean AJ, Dudley FJ. Renal sodium retention in cirrhosis: tubular site and relation to hepatic dysfunction. HEPATOLOGY 1988; 8: 831–836.
- 107 Wensing G, Branch RA. Phenobarbital influences the development of sodium retention in liver disease induced by bile duct ligation in the rat. HEPATOLOGY 1990; 11: 773–778.
- 108 Wensing G, Sabra R, Branch RA. The onset of sodium retention in experimental cirrhosis in rats is related to a critical threshold of liver function. HEPATOLOGY 1990; 11: 779–786.
- 109 Gustavson LE, Legler UF, Benet LZ. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 1986; 62: 234–237.
- 110 Scavone JM, Ochs HR, Greenblatt DJ, Matlis R. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. Eur J Clin Pharmacol 1988; 35: 105–108.
- 111 Bannister P, Oakes J, Sheridan P, Losowsky MS. Sex hormone changes in chronic liver disease. Q J Med (new series) 1987; 630: 305–313.
- 112 Sonne J, Dragstedt J, Loft S, Døssing M, Andreasen F. Influence of a very low calorie diet on the clearance of oxazepam and antipyrine. Eur J Clin Pharmacol 1989; 36: 407–409.
- 113 Mehta S, Kalsi HK, Jayaraman S, Mathur VS. Chloramphenicol metabolism in children with protein-calorie malnutrition. Am J Clin Nutr 1975; 28: 977–981.
- 114 Stephenson FA. Benzodiazepines in the brain. Trends Neurosci 1987; 10: 185–186.
- 115 Mullen KD, Mendelson WB, Martin JV, Bassett ML, Jones EA. Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy? Lancet 1988; 1: 457–459.
- 116 Laidlaw J, Read AE, Sherlock S. Morphine tolerance in hepatic cirrhosis. Gastroenterology 1961; 389–396.
- 117 Branch RA, Morgan MH, James J, Read AE. Intravenous administration of diazepam in patients with chronic liver disease. Gut 1976; 17: 975–983.
- 118 Bakti G, Fisch H, Karlaganis G, Minder C, Bircher J. Mechanisms of the excessive sedative response of cirrhosis to benzodiazepines: model experiments with triazolam. HEPATOLOGY 1987; 7: 629–638.
